Novavax NVX-CoV2373 Variant-Specific Immune Responses 2021

Clinical development overview of Novavax's NVX-CoV2373 COVID-19 vaccine candidate, detailing Phase 1 through Phase 3 trial results across multiple geographies and demonstrating variant-specific immune responses following primary and boosted vaccination. Presents data from licensure-enabling safety and efficacy studies conducted in the U.S., Mexico, United Kingdom, South Africa, and Australia.